<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140749</url>
  </required_header>
  <id_info>
    <org_study_id>NL46640.081.14</org_study_id>
    <nct_id>NCT02140749</nct_id>
  </id_info>
  <brief_title>Trial on Short-chain Fructooligosaccharides, Microbiota, and Constipation in Adults</brief_title>
  <acronym>TOMCAT</acronym>
  <official_title>Randomized, Placebo-controlled Double-blind Cross-over Study to Evaluate the Effects of Short-chain Fructooligosaccharides on Stool Frequency in Constipated Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NIZO Food Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ingredion Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NIZO Food Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The dietary short-chain fructooligosaccharides have been shown to increase fecal&#xD;
      bacterial mass and fermentation metabolites which might stimulate gut motility. Therefore,&#xD;
      these dietary non-digestible carbohydrates might relieve functional constipation.&#xD;
&#xD;
      Objective: Study the effect of short-chain fructooligosaccharides on functional constipation.&#xD;
&#xD;
      Study design: A 16-week, randomized, placebo-controlled, double-blind cross-over trial with&#xD;
      intervention periods of 4 weeks with a run-in period of 4 weeks and a wash-out period of 4&#xD;
      weeks.&#xD;
&#xD;
      Study population: Human subjects with functional constipation according to ROMEIII criteria&#xD;
      (total n=120; male and female; 18-75 yr).&#xD;
&#xD;
      Intervention: Placebo and one out of 3 dosages of short-chain fructo-oligosaccharides,&#xD;
      (Degree of Polymerisation of 3-5; 2, 4 and 8 g/day) for 4 weeks. scFOS will be given as oral&#xD;
      chews.&#xD;
&#xD;
      Main study parameters: The primary parameter is the number of complete bowel movements per&#xD;
      day in subjects with functional constipation according to Rome III criteria. Secondary&#xD;
      outcomes are Stool consistency (Bristol Stool Scale), Stool frequency, Severity of symptoms&#xD;
      (Constipation Scoring System; CSS) and Quality of Life (Patient Assessment of Constipation&#xD;
      Quality of Life; PAC-QoL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool frequency (Number of complete bowel movements per day)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool consistency (Bristol Stool Scale)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of symptoms (Constipation Scoring System; CSS)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Patient Assessment of Constipation Quality of Life; PAC-QoL)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>sc-FOS 2g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sc-FOS 4g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sc-FOS 8g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sc-FOS 2g/day</intervention_name>
    <description>Chewing tablets containing Short-chain fructooligosaccharides 2g/day</description>
    <arm_group_label>sc-FOS 2g/day</arm_group_label>
    <other_name>FOS</other_name>
    <other_name>Oligofructose</other_name>
    <other_name>scFOS</other_name>
    <other_name>Short-chain fructo-oligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sc-FOS 4g/day</intervention_name>
    <description>Chewing tablets containing short-chain Fructooligosaccharides 4g/day</description>
    <arm_group_label>sc-FOS 4g/day</arm_group_label>
    <other_name>FOS</other_name>
    <other_name>Oligofructose</other_name>
    <other_name>scFOS</other_name>
    <other_name>Short-chain fructo-oligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sc-FOS 8g/day</intervention_name>
    <description>Chewing tablets containing short-chain Fructooligosaccharides 8g/day</description>
    <arm_group_label>sc-FOS 8g/day</arm_group_label>
    <other_name>FOS</other_name>
    <other_name>Oligofructose</other_name>
    <other_name>scFOS</other_name>
    <other_name>Short-chain fructo-oligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Chewing tablets without short-chain Fructooligosaccharides</description>
    <arm_group_label>sc-FOS 2g/day</arm_group_label>
    <arm_group_label>sc-FOS 4g/day</arm_group_label>
    <arm_group_label>sc-FOS 8g/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 yr&#xD;
&#xD;
          -  Agree to study design (signed informed consent)&#xD;
&#xD;
          -  At least two of the following symptoms ≥25% of the time with criteria fulfilled for&#xD;
             the last 3 months with symptom onset at least 6 months prior to inclusion (ROME III&#xD;
             criteria for functional constipation):&#xD;
&#xD;
               -  straining, lumpy or hard stool&#xD;
&#xD;
               -  sensation of incomplete evacuation&#xD;
&#xD;
               -  sensation of anorectal obstruction ⁄ blockage&#xD;
&#xD;
               -  use of manual manoeuvres&#xD;
&#xD;
               -  &lt;3 bowel movements per week&#xD;
&#xD;
          -  Availability of internet connection&#xD;
&#xD;
          -  BMI 20-30&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Willingness to abstain from functional ingredients and such as probiotics, prebiotics&#xD;
             and foods containing high amounts of fermentable fibers and laxatives starting 1 month&#xD;
             prior to start of the study as well as during the washout period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently participating in another clinical trial&#xD;
&#xD;
          -  Drug usage&#xD;
&#xD;
          -  Excessive alcohol usage (&gt;4 consumptions/day or &gt;20 consumptions/week)&#xD;
&#xD;
          -  Pregnancy or lactating&#xD;
&#xD;
          -  Underlying disease of the GI-tract or previous laparotomy, except cholecystectomy and&#xD;
             appendectomy&#xD;
&#xD;
          -  Use of antibiotics within 1 month prior to inclusion&#xD;
&#xD;
          -  Vegetarians&#xD;
&#xD;
          -  Weight loss &gt; 5 kg within 1 month prior to inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra ten Bruggencate, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIZO Food Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIZO food research</name>
      <address>
        <city>Ede</city>
        <state>Gelderland</state>
        <zip>6718ZB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.nizo.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifidobacteria</keyword>
  <keyword>Bristol Stool Scale</keyword>
  <keyword>Constipation</keyword>
  <keyword>Diet</keyword>
  <keyword>Fructooligosacchardes</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Oligofructose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

